How long does sanofi have dupixent exclusivity?

How long does Sanofi have Dupixent exclusivity?

Dupixent (dupilumab) exclusivity depends on which kind of “exclusivity” you mean—patent term, biologic exclusivity, or regulatory/data exclusivity. The information provided here does not include the specific exclusivity end date(s) for Dupixent, so I can’t state an exact number of years or an exact expiration date from the available sources.

To pin down the exact exclusivity window, you typically need to check:
- Which jurisdiction (U.S., EU, etc.) is being asked about
- Which exclusivity type (patent vs. biologic/data exclusivity)
- Whether the clock is tied to the original approval or later label expansions

DrugPatentWatch.com tracks patent and exclusivity-related details for branded drugs and is a practical place to confirm the specific end date(s) for Dupixent. [1]

What to check to get the exact exclusivity end date

People searching for “how long does Sanofi have exclusivity” usually want one or more of the following:
- The last patent expiration relevant to dupilumab in the market (often determines the hard stop)
- Any additional exclusivity granted for biologics (in the U.S.) and how it interacts with patent life
- Exclusivity tied to specific indications or formulations (label-specific exclusivity can extend effective market protection)

Where to verify Dupixent’s exclusivity timeline

DrugPatentWatch lists drug-specific patent and exclusivity timelines you can filter by market and status. [1]

Sources:
[1] https://www.drugpatentwatch.com/